Applicant: Erik Buntinx Serial No.: 10/752,423 Filed: January 6, 2004

page 2 of 14

## Amendments to the Claims:

Please cancel claims 2, 3, 4, 6, 8, 11-15 and 17-63 without prejudice or disclaimer, and amend claims 1, 7, 9 and 10 as set forth below.

1. (Currently amended) A method for treating an anxiety disease or disorder with an underlying dysregulation of emotional functionality comprising administering to a patient pipamperone a compound having (i) a selective affinity for the Dopamine 4 (D4) receptor with a pKi value equal to or higher than 8 towards the D4 receptor and less than 8 towards other Dopamine receptors, and (ii) a selective affinity for the 5 HT2A receptor with a pKi value equal to or higher than 8 towards the 5 HT2A receptor and less than 8 towards other 5HT receptors, wherein said compound is administered to said patient in a dose ranging between 5 and 15 mg of the active ingredient, wherein a selective serotonin re-uptake inhibitor (SSRI) is administered to the patient simultaneously with, separate from or sequential to the administration of pipamperone to augment the therapeutic effect of said SSRI or to provide a faster onset of the therapeutic effect of said SSRI.

## 2-6. (Canceled)

- 7. (Currently amended) The method of claim 1, 4, wherein pipamperone the first compound is administered daily at least one day before administering said <u>SSRI</u> second compound.
  - 8. (Canceled)
- 9. (Currently amended) The method of claim 1, 8, wherein said selective serotonin re-uptake inhibitor is chosen from the group consisting of CITALOPRAM,

Applicant: Erik Buntinx Serial No.: 10/752,423 Filed: January 6, 2004

page 3 of 14

fluoxetine, venlafaxine, fluoxamine, paroxetine, sertraline, milnacipran and duloxetine, or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof.

10. (Currently amended) The method of claim  $\underline{1}$ , 9 wherein said serotonin reuptake inhibitor is CITALOPRAM and is administered in a dose ranging between 10 and 40 mg of the active ingredient.

11-63. (Canceled)